🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Spain / NCT05945017
Active, not recruiting Not applicable

Probiotics and the Neurodevelopment in the Premature Infant <32 Weeks Gestational Age and <1500g

NCT05945017 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2014-01-01
Last updated
2023-08-14

Condition(s) studied

Infant, Newborn, DiseasesInfant Development

Investigational drug(s) / intervention(s)

Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748

Study summary

Unicentric, quasi-experimental, cohort study to evaluate the effect of combining two probiotics (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748) in the neurodevelopment of preterm neonates below 32 weeks' gestation and a birthweight under 1,500 g. This probiotic combination has shown to be safe and beneficial in premature neonates in the prevention of NEC. The investigators hypothesised that this mixture would contribute to better neurodevelopmental outcomes of preterm neonates when assessed at 24 months corrected age. Additionally, neurodevelopment improved would be more relevant at 6 years of age, together with a better pattern of neuronal plasticity biomarkers.

Secondarily, this mixture of probiotics could reduce NEC, LOS, intraventricular haemorrhage and neonatal mortality in accordance with previous studies.

Eligibility

Sex
ALL
Min age
—
Max age
32 Weeks
Healthy volunteers
No
Inclusion Criteria: * Premature infants under 32 weeks gestational age and less than 1500g birthweight. * Born at BCNatal Hospital Clínic between years 2014-2019. Exclusion Criteria: * All neonates presenting with suspected congenital anomalies, inborn errors of metabolism, or genetic defects were excluded. * Infants with a suspected syndrome, or who have suffered events beyond the neonatal period, not related to prematurity, that could entail impairment in neurodevelopment (severe cranioencephalic trauma, oncological process, meningitis, or exposure to toxic substances)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Neonataology Service, BCNatal Hospital Clinic Seu Maternitat Barcelona Spain

More Fundacion Clinic per a la Recerca Biomédica trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05945017 on ClinicalTrials.gov ↗ ← All trials in Spain